Laura Joszt, MA

Using lower-cost generic drugs that are as safe and effective as the brand-name versions could have saved more than $900 million in Medicare in 2016, according to research published in JAMA.

Payment reform efforts that don't engage patients are missing out on an opportunity for greater improvements, especially in cancer, where patients face substantial cost sharing.

Accountable care organizations (ACOs), either directly or indirectly, are affecting physician employment patterns in regions where they have high penetration.

A new technology platform utilizing artificial intelligence (AI) could change how drug combinations are designed and help doctors to identify optimal personalized drug combinations for patients with multiple myeloma.

Chronic diseases, insufficient access to care, and social determinants of health are targets that can help reduce maternal mortality.

The FDA has approved a new drug to treat 2 rare types of non-Hodgkin lymphoma based on phase 3 clinical trial results that found mogamulizumab-kpkc improved progression-free survival and had a higher overall response rate compared with the chemotherapy vorinostat.

A new rule in the Medicare Access and CHIP Reauthorization Act’s 2019 Quality Payment Program and the proposed 2019 Medicare Physician Fee Schedule could negatively affect the quality of cancer care for Medicare beneficiaries, according to the American Society of Clinical Oncology.

While more healthcare organizations are understanding the benefit of upstream interventions, sustainable financing is still lacking.

A new report from the Congressional Budget Office explored Medicaid managed care’s enrollment and spending and factors that affect both.

A progress report from the Leukemia & Lymphoma Society highlighted policy measures that have eased the burden on patients, but also noted where more work is needed.

The Trump administration will allow Medicare Advantage plans to negotiate prices for Part B drugs by providing them the opportunity to create plans that utilize step therapy. However, some in the healthcare industry view step therapy, also known as "fail first," as dangerous to patients with life-threatening diseases, such as cancer.

Advances in Hodgkin lymphoma treatment has led to high survival rates, but adolescents and young adults, who represent the largest age group affected by the disease, face lifelong morbidities from clinical trials. New analytic methods could help inform future protocol changes.

If patients want to be empowered to control their healthcare and if the United States wants healthcare to be economically efficient, then interoperability is critical, said Don Rucker, MD, the National Coordinator for Health Information Technology (IT), during the Office of the National Coordinator for Health IT’s 2nd Interoperability Forum. He was followed by CMS Administrator Seema Verma, who disparaged the current technological situation and painted a future where health data followed the patient and can be shared at the press of a button.

Payment reforms efforts are still facing barriers, but buy-in and increased demand from self-insured employers can help spur widespread adoption of new payment models that will lead to health delivery system reforms, according to a commentary published in New England Journal of Medicine.

If Medicare was allowed to negotiate drug prices, the Medicare Part D program could save $2.8 billion in 1 year on the 20 most commonly prescribed drugs alone, according to a new report from Senator Claire McCaskill, D-Missouri, the top-ranking Democrat on the Senate Homeland Security and Governmental Affairs Committee.

In addition to survival among adolescents and young adults (AYAs) with hematological malignancies lagging behind that of children and older adults, AYAs also face unique challenges related to their physical, psychosocial, and economic circumstances.

Community health centers are on the front lines of addressing the opioid epidemic, and those in Medicaid expansion states seem to be better equipped to respond to the crisis.

Treatment options for patients with acute myeloid leukemia (AML) who relapse after an allogeneic hematopoietic cell transplant (allo-HCT) are limited, but those who are able to receive intensive interventions receive a second allo-HCT or donor lymphocyte infusion. A study in JAMA Oncology sought to compare the 2 options for patients who relapse.

Health plans continue to show interest in expanding outcomes-based contracts, according to an Avalere Health study that also found cardiovascular diseases, infectious diseases, and oncology represent the most common therapeutic areas to have these contracts.

A second biosimilar to Amgen’s Neupogen, which treats neutropenia, has been approved in the United States. The FDA approved Pfizer’s filgrastim-aafi, which will be sold under the brand name Nivestym. Zarxio (filgrastim-sndz) was the first filgrastim biosimilar approved by the FDA in 2015.

Adam Boehler, director of the Center for Medicare & Medicaid Innovation, is taking on an additional role as the senior advisor for value-based transformation and innovation. He represents the last departmental appointment as part of HHS Secretary Alex Azar's 4 priority areas.

The FDA approved the first targeted therapy for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. In addition, FDA also approved a companion diagnostic to be used to detect the specific mutations in the IDH1 gene.

New tools from the American College of Chest Physicians' CHEST Foundation, the Allergy & Asthma Network, and the American College of Allergy, Asthma & Immunology can help clinicians and patients to work together to choose the best treatment and increase adherence.

For vulnerable populations, their health and healthcare issues may be exacerbated by social factors. Here are just 5 vulnerable populations who experience greater risk factors, worse access to care, and increased morbidity and mortality compared with the general population.

The FDA has expanded its approval of ribociclib (Kisqali) to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer under 2 new pilot programs to make the development and review of cancer drugs more efficient.

After 5 years of research, the Hutchinson Institute for Cancer Outcomes Research has released a report that is the first in the nation to publicly report clinic-level quality measures linked to cost in oncology.

A new road map highlights how to overcome barriers to integrating person-centered care and evidence-based research at hospitals caring for vulnerable populations.

Quality measurement has been around for nearly 2 decades and in that time measures have evolved and also proliferated to the point of placing considerable burden on physicians and health systems. New efforts are being made to streamline current measures, fill in gaps, and harmonize measures across programs.

Acute myeloid leukemia can often appear suddenly in patients, without any detectable early symptoms. However, new research has identified the origins of AML, which can be detectable more than 5 years before the disease develops.

Psychological stress and emotional well-being are important targets for multiple sclerosis (MS) research and clinical care. Mood disorders can adversely impact functioning, quality of life, and treatment adherence, and increase the risk of suicide.